Overview

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Status:
Terminated

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Panobinostat and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving panobinostat together with everolimus and to see how well they work in treating patients with metastatic or unresectable renal cell cancer that does not respond to treatment with sunitinib malate or sorafenib tosylate

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Roswell Park Cancer Institute

Collaborators:

National Cancer Institute (NCI)
Novartis

Treatments:

Everolimus
Histone Deacetylase Inhibitors
Panobinostat
Sirolimus